Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment

被引：3

作者：

Sun, Junzhong ^{[1
]}

Xu, Yin ^{[2
]}

Song, Santai ^{[3
]}

Wu, Zuze ^{[2
]}

Duan, Haifeng ^{[2
]}

机构：

[1] PLA, Gen Hosp, Clin Dept 304, Beijing, Peoples R China

[2] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China

[3] Acad Mil Med Sci, Affiliated Hosp 307, Beijing, Peoples R China

来源：

PHARMACEUTICAL BIOLOGY | 2011年 / 49卷 / 11期

基金：

美国国家科学基金会;

关键词：

Chemosensitizer; breast neoplasms; knock down; SMALL-MOLECULE; IN-VITRO; THERAPY; THERAPEUTICS; INHIBITION; AP-12009; TUMORS; MODEL;

D O I：

10.3109/13880209.2011.575792

中图分类号：

Q94 [植物学];

学科分类号：

071001 ;

摘要：

Context: Human epidermal growth factor receptor 2 (HER2) is one of the oncogenes closely associated with the development and prognosis of breast carcinoma. Down-regulation of HER2 mRNA by antisense oligodeoxynucleotide (ASO) HER2 has been suggested to be a feasible treatment for patients with breast carcinoma. Objective: The antitumor effects of ASO HA6722 were investigated in vitro and in vivo. Materials and methods: In this study, SK-BR-3, a HER2-overexpressing breast carcinoma cell line, was used as the model for in vitro experiments. Inhibitory effects of the ASO HA6722 were detected by methyl-thiazoldiphenyl tetrazolium (MTT) assay. Meanwhile, HER2 mRNA levels were monitored by reverse transcription polymerase chain reaction (RT-PCR). The in vivo antitumor effects were evaluated in nude mice xenograft model. Results: Our results showed that HA6722 alone could inhibit the growth of SK-BR-3 cells in a dose-dependent manner with the IC(50) value of 41.8 +/- 8.1 nM. In addition, the antitumor effect of docetaxel (TXT) could be sensitized by low dose of HA6722 both in vitro and in vivo, suggesting that ASO HA6722 could inhibit the growth of breast cancer cells and enhance the cytotoxic effects of TXT. Discussion and conclusion: The combination treatment of TXT and HA6722 could be a more effective approach for breast cancer treatment. The future study should focus on the antitumor effect in other models.

引用

页码：1167 / 1172

页数：6

共 24 条

[1]

Alpaugh ML, 1999, CANCER RES, V59, P5079

[2] Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model [J].

Canales, BK ;

Li, YM ;

Thompson, MG ;

Gleason, JM ;

Chen, Z ;

Malaeb, B ;

Corey, DR ;

Herbert, BS ;

Shay, JW ;

Koeneman, KS .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (02) :141-151

[3] HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients [J].

Del Mastro, L ;

Bruzzi, P ;

Nicolò, G ;

Cavazzini, G ;

Contu, A ;

D'Amico, M ;

Lavarello, A ;

Testore, F ;

Castagneto, B ;

Aitini, E ;

Perdelli, L ;

Bighin, C ;

Rosso, R ;

Venturini, M .

BRITISH JOURNAL OF CANCER, 2005, 93 (01) :7-14

[4] Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer [J].

Fujii, Teruhiko ;

Yokoyama, Goro ;

Takahashi, Hiroki ;

Namoto, Roka ;

Nakagawa, Shino ;

Toh, Uhi ;

Kage, Masayoshi ;

Shirouzu, Kazuo ;

Kuwano, Michihiko .

BREAST CANCER, 2008, 15 (01) :73-78

[5] Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells [J].

Gao, P. ;

Zhou, G. -Y ;

Lei, D. -P ;

Zhang, X. -F ;

Li, Li ;

Xu, J. -W ;

Lin, X. -Y .

CYTOTHERAPY, 2007, 9 (08) :795-801

[6] Breast cancer 2004: Progress and promise on the clinical front [J].

Gralow, Julie R. .

PHYSICA MEDICA, 2006, 21 :2-2

[7] Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways. [J].

Hatake K. ;

Tokudome N. ;

Ito Y. .

Breast Cancer, 2007, 14 (2) :132-149

[8] Inhibition of TGF-β2 with AP 12009 in recurrent malignant gliomas:: From preclinical to phase I/II studies [J].

Hau, Peter ;

Jachimczak, Piotr ;

Schlingensiepen, Reimar ;

Schulmeyer, Frank ;

Jauch, Tanya ;

Steinbrecher, Andreas ;

Brawanski, Alexander ;

Proescholdt, Martin ;

Schlaier, Juergen ;

Buchroithner, Johanna ;

Pichler, Josef ;

Wurm, Gabriele ;

Mehdorn, Maximilian ;

Strege, Rainer ;

Schuierer, Gerhard ;

Villarrubia, Victoria ;

Fellner, Franz ;

Jansen, Olav ;

Straube, Thorsten ;

Nohria, Virinder ;

Goldbrunner, Michael ;

Kunst, Mechthild ;

Schmaus, Susanne ;

Stauder, Gerhard ;

Bogdahn, Ulrich ;

Schlingensiepen, Karl-Hermann .

OLIGONUCLEOTIDES, 2007, 17 (02) :201-212

[9] Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer [J].

Lipton, A ;

Ali, SM ;

Leitzel, K ;

Demers, L ;

Chinchilli, V ;

Engle, L ;

Harvey, HA ;

Brady, C ;

Nalin, CM ;

Dugan, M ;

Carney, W ;

Allard, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1467-1472

[10] Update on HER-2 as a target for cancer therapy - Herceptin in the clinical setting [J].

Miles, DW .

BREAST CANCER RESEARCH, 2001, 3 (06) :380-384

← 1 2 3 →